Polyethylene glycols: An effective strategy for limiting liver ischemia reperfusion injury
Liver ischemia-reperfusion injury(IRI) is an inherent feature of liver surgery and liver transplantation in which damage to a hypoxic organ(ischemia) is exacerbated following the return of oxygen delivery(reperfusion). IRI is a major cause of primary nonfunction after transplantation and may lead to...
Saved in:
Published in: | World journal of gastroenterology : WJG Vol. 22; no. 28; pp. 6501 - 6508 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
Baishideng Publishing Group
28-07-2016
Baishideng Publishing Group Inc |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Liver ischemia-reperfusion injury(IRI) is an inherent feature of liver surgery and liver transplantation in which damage to a hypoxic organ(ischemia) is exacerbated following the return of oxygen delivery(reperfusion). IRI is a major cause of primary nonfunction after transplantation and may lead to graft rejection, regardless of immunological considerations. The immediate response involves the disruption of cellular mitochondrial oxidative phosphorylation and the accumulation of metabolic intermediates during the ischemic period, and oxidative stress during blood flow restoration. Moreover, a complex cascade of inflammatory mediators is generated during reperfusion, contributing to the extension of the damage and finally to organ failure. A variety of pharmacological interventions(antioxidants, anticytokines, etc.) have been proposed to alleviate graft injury but their usefulness is limited by the local and specific action of the drugs and by their potential undesirable toxic effects. Polyethylene glycols(PEGs), which are non-toxic water-soluble compounds approved by the FDA, have been widely used as a vehicle or a base in food, cosmetics and pharmaceuticals, and also as adjuvants for ameliorating drug pharmacokinetics. Some PEGs are also currently used as additives in organ preservation solutions prior to transplantation in order to limit the damage associated with cold ischemia reperfusion. More recently, the administration of PEGs of different molecular weights by intravenous injection has emerged as a new therapeutic tool to protect liver grafts from IRI. In this review, we summarize the current knowledge concerning the use of PEGs as a useful target for limiting liver IRI. |
---|---|
Bibliography: | Gianfranco Pasut;Arnau Panisello;Emma Folch-Puy;Alexandre Lopez;Carlos Castro-Benítez;Maria Calvo;Teresa Carbonell;Agustín García-Gil;René Adam;Joan Roselló-Catafau;Department of Pharmaceutical and Pharma- cological, University of Padova and Veneto Institute of Oncology, IRCCS;Experimental Pathology Department, Institute of Biomedical Research of Barcelona;Centre Hépatobiliaire, AP-HP H?pital Paul Brousse, Inserm U935, Université Paris-Sud, Villejuif, 75008 Paris, France;Unitat de Microscòpia òptic Avan?ada, CCi TUB, Centre Científics i Tecnològics, Faculty of Medicine, University of Barcelona;Physiology Department, Faculty of Biology, Universitat de Barcelona;Hospital Clinico de Zaragoza ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 Telephone: +34-93-3638333 Fax: +34-93-3638301 Correspondence to: Joan Roselló-Catafau, PhD, Experimental Pathology Department, Institute of Biomedical Research of Barcelona, Rosselló 161, 08036-Barcelona, Catalonia, Spain. jrcbam@iibb.csic.es Supported by Fondo de Investigaciones Sanitarias, Ministerio de Economía y Competitividad (Madrid, Spain), No. PI15/00110. Author contributions: All authors contributed equally to the writing of the manuscript and approved the final version. |
ISSN: | 1007-9327 2219-2840 |
DOI: | 10.3748/wjg.v22.i28.6501 |